Rupatadine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C26H26ClN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2AE8M83G3E, chemically known as 8-chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridyl)methyl)-4-piperidylidene)-5h-benzo(5,6)cyclohepta(1,2-b)pyridine but generally known as rupatadine, which bears US NIH Compound Identifier 133017. European Medicines Agency schedules Rupatadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10406MIG. The term RUPATADINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules rupatadine in its Anatomical Therapeutic Chemical (ATC) Classification. RUPATADINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rupatadine under HS 29333999 and SITC 51574. As of Q4 2014, RUPATADINE remains the US FDA Preferred Term for this commodity. Rupatadine bears US NLM identifiers UMLS ID C0534301 and NCI Concept Code C73055. SMILES: CLC1CC2C(/C(=C3\CCN(CC3)CC3CC(CNC3)C)C3NCCCC3CC2)CC1.